Economic burden of moderate to severe plaque psoriasis in Canada

International Journal of Dermatology

Volumn 51, Issue 12, 2012, Pages 1432-1440

  Levy, Adrian R ^a,b   Davie, Alison M ^b   Brazier, Nicole C ^c   Jivraj, Farah ^c   Albrecht, Lorne E ^d   Gratton, David ^e   Lynde, Charles W ^f  

^a DALHOUSIE UNIVERSITY   (Canada)

^b ICON PLC   (United Kingdom)

^c Janssen Ortho Inc   (Canada)

^d Guildford Dermatology   (Canada)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^f Lynderm Research Inc Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CANADA; COST; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTOTHERAPY; PRODUCTIVITY; PSORIASIS VULGARIS; QUALITY OF LIFE; SYSTEMIC THERAPY; TOPICAL TREATMENT;

ABSENTEEISM; ADULT; AMBULATORY CARE FACILITIES; CANADA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH EXPENDITURES; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; PSORIASIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SICK LEAVE;

EID: 84869754460     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05359.x     Document Type: Article

References (43)

1. Canadian Dermatology Association. Canadian Guidelines for the Management of Plaque Psoriasis. Canadian Dermatology Association, 2009. Available at: http://www.dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf. [Accessed October 20, 2011].
2. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
3. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
4. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-1499.
5. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
6. Raychaudhuri SP, Navare T, Gross J, Raychaudhuri SK. Clinical course of psoriasis during pregnancy. Int J Dermatol 2003; 42: 518-20.
7. Guenther L, Langley RG, Shear NH, et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2004; 8: 321-337.
8. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512-518.
9. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
10. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.
11. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
12. Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010; 24: 1075-1082.
13. Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963-971.
14. Sander HM, Morris LF, Phillips CM, et al. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28: 422-425.
15. Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004. A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol 2006; 55: 490-500.
16. Pariser DM, Bagel J, Gelfand JM, et al. National psoriasis foundation clinical consensus on disease severity. Arch Dermatol 2007; 143: 239-242.
17. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-867.
18. Basra MK, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol 2008; 159: 997-1035.
19. British Columbia Ministry of Health. BC PharmaCare Low Cost Alternative Reference Drug Program Booklet. Victoria: British Columbia Ministry of Health, 2008.
20. Ministère de la Santé et des Services Sociaux du Québec. Laboratoire de Biologie Médicale Mesure de la Production. Québec: Ministère de la Santé et des Services Sociaux du Québec, 2007.
21. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit Program E-formulary. Ontario Ministry of Health and Long Term Care, 2008. Available at: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html. [Accessed October 20, 2011].
22. Ontario Ministry of Health and Long Term Care. Ontario Health Insurance Schedule of Fees and Benefits. Toronto: Ontario Ministry of Health and Long Term Care, 2008.
23. RAMQ. List of medications. Quebec Government Programs and Services 2010. Available at: http://www.ramq.gouv.qc.ca/en/regie/lois/liste_med.shtml. [Accessed October 20, 2011].
24. RAMQ. Spécialistes Tarification des Visites. Québec: RAMQ, 2007.
25. Fleiss JL, Levin B, Paik MC. Statistical Methods for Rates and Proportions, 3rd edn. Hoboken, NJ: John Wiley & Sons, Inc, 2003.
26. Department of Justice Canada. Canada labour code, 2008.
27. Statistics Canada Catalogue no. 72-002-X. Statistics Canada 2008 (Tables 282-0069 and 282-0073).
28. Statistics Canada Catalogue no. 72-002-X. Statistics Canada 2008 (Table 281-0044).
29. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Measurement 1960; 20: 37-46.
30. Canadian Dermatology Association. Psoriasis. www dermatology ca 2008 Available at: http://www.dermatology.ca/patients_public/info_patients/psoriasis/index.html. [Accessed October 20, 2011].
31. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-271.
32. Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatol Treatment 2006; 17: 294.
33. Anonymous. Unmet needs in the management of plaque psoriasis. Manag Care 2009; 18(Suppl. 1): 1-6.
34. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg 2004; 8: 310-320.
35. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of national psoriasis foundation survey J Am Acad Dermatol 2007; 57: 957-962.
36. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
37. Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol 2008; 58: 964-969.
38. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol 2004; 136-139. Symposium.
39. Wasel N, Poulin Y, Andrew R, et al. A Canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients. J Cutan Med Surg 2009; 13: 294-302.
40. Schoffski O, Augustin M, Prinz J, et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges 2007; 5: 209-218.
41. Goodless D. Psoriasis flare. http://www. psoriasis about.com 2008 [Accessed October 20, 2011].
42. Johannesson M, Borgquist L, Jonsson B. The costs of treating hypertension in Sweden. An empirical investigation in primary health care. Scand J Prim Health Care 1991; 9: 155-160.
43. Jowett S, Bryan S, Mahe I, et al. A multinational investigation of time and traveling costs in attending anticoagulation clinics. Value Health 2008; 11: 207-212.